Journal Article > LetterFull Text
PLOS Glob Public Health. 17 October 2024; Volume 4 (Issue 10); e0003714.; DOI:10.1371/journal.pgph.0003714
McNab C, Torreele E, Alakija A, Aluso A, Cárdenas M, et al.
PLOS Glob Public Health. 17 October 2024; Volume 4 (Issue 10); e0003714.; DOI:10.1371/journal.pgph.0003714
Journal Article > LetterFull Text
Lancet Infect Dis. 1 April 2023; Volume 23 (Issue 4); 407-408.; DOI:10.1016/S1473-3099(23)00127-5
Torreele E, Boum Y, Adjaho I, Alé FGB, Issoufou SH, et al.
Lancet Infect Dis. 1 April 2023; Volume 23 (Issue 4); 407-408.; DOI:10.1016/S1473-3099(23)00127-5
Journal Article > CommentaryFull Text
Lancet Infect Dis. 19 January 2023; Online ahead of print; DOI:10.1016/S1473-3099(22)00810-6
Torreele E, Boum Y, Adjaho I, Alé FGB, Issoufou SH, et al.
Lancet Infect Dis. 19 January 2023; Online ahead of print; DOI:10.1016/S1473-3099(22)00810-6
Three years since proving effective for Ebola virus disease in a clinical trial, two breakthrough treatments are registered and stockpiled in the USA but still not registered and generally available in the countries most affected by this deadly infection of epidemic potential. Analysing the reasons for this, we see a fragmentation of the research and development value chain, with different stakeholders taking on different steps of the research and development process, without the public health-focused leadership needed to ensure the end goal of equitable access in countries where Ebola virus disease is prevalent. Current financial incentives for companies to overcome market failures and engage in epidemic-prone diseases are geared towards registration and stockpiling in the USA, without responsibility to provide access where and when needed. Ebola virus disease is the case in point, but not unique—a situation seen again for mpox and likely to occur again for other epidemics primarily affecting disempowered communities. Stronger leadership in African countries will help drive drug development efforts for diseases that primarily affect their communities, and ensure all partners align with and commit to an end-to-end approach to pharmaceutical development and manufacturing that puts equitable access when and where needed at its core.
Journal Article > CommentaryFull Text
Nature. 9 February 2022; Volume 602 (Issue 7896); 207-210.; DOI:10.1038/d41586-022-00324-y
Swaminathan S, Pecoul B, Abdullah H, Christou C, Gray G, et al.
Nature. 9 February 2022; Volume 602 (Issue 7896); 207-210.; DOI:10.1038/d41586-022-00324-y
Journal Blog > Perspective
BMJ. 11 July 2019
Torreele E
BMJ. 11 July 2019
Journal Article > EditorialFull Text
Bull World Health Organ. 1 May 2019; Volume 97 (Issue 5); 311-311A.; DOI:10.2471/BLT.19.234468
Tatay M, Torreele E
Bull World Health Organ. 1 May 2019; Volume 97 (Issue 5); 311-311A.; DOI:10.2471/BLT.19.234468
Journal Article > Short ReportFull Text
PLOS Med. 18 April 2017; Volume 14 (Issue 4); e1002276.; DOI:10.1371/journal.pmed.1002276
Balasegaram M, Kolb P, McKew J, Menon J, Olliaro PL, et al.
PLOS Med. 18 April 2017; Volume 14 (Issue 4); e1002276.; DOI:10.1371/journal.pmed.1002276
Journal Article > CommentaryFull Text
BMJ Glob Health. 1 February 2021; Volume 6 (Issue 2); e005306.; DOI:10.1136/bmjgh-2021-005306
Boum Y II, Ouattara AK, Torreele E, Okonta C
BMJ Glob Health. 1 February 2021; Volume 6 (Issue 2); e005306.; DOI:10.1136/bmjgh-2021-005306
SUMMARY POINTS
• Limited access to vaccines by African nations as Africa has been side-lined in the race to secure vaccines for COVID-19.
•. Uniform thinking and planning overlook distinct country realities that may imply different COVID-19 responses, including vaccination strategies, and that local stakeholders and communities have a central role in designing and implementing successful public health interventions.
•. The distribution of COVID-19 vaccines should be part of an integrated and broader strategy, both to curb COVID-19 and also to improve life and well-being of the target community.
•. The backdrop of Africa in the COVID-19 vaccine race highlights the urgency for Africans to invest in research to ensure that strategies are adapted to the Africa context and not just imported as the COVID-19 vaccine will be.
• Limited access to vaccines by African nations as Africa has been side-lined in the race to secure vaccines for COVID-19.
•. Uniform thinking and planning overlook distinct country realities that may imply different COVID-19 responses, including vaccination strategies, and that local stakeholders and communities have a central role in designing and implementing successful public health interventions.
•. The distribution of COVID-19 vaccines should be part of an integrated and broader strategy, both to curb COVID-19 and also to improve life and well-being of the target community.
•. The backdrop of Africa in the COVID-19 vaccine race highlights the urgency for Africans to invest in research to ensure that strategies are adapted to the Africa context and not just imported as the COVID-19 vaccine will be.
Journal Article > EditorialFull Text
Bull World Health Organ. 1 May 2017; Volume 95 (Issue 5); DOI:10.2471/BLT.17.194837
Brigden G, Castro JL, Ditiu L, Gray G, Hanna D, et al.
Bull World Health Organ. 1 May 2017; Volume 95 (Issue 5); DOI:10.2471/BLT.17.194837
Journal Article > ResearchFull Text
Lancet. 13 May 2006; Volume 367 (Issue 9522); DOI:10.1016/S0140-6736(06)68672-8
Chirac P, Torreele E
Lancet. 13 May 2006; Volume 367 (Issue 9522); DOI:10.1016/S0140-6736(06)68672-8